What does the data say about Yervoy (ipilimumab) toxicity in men vs women?
The provided information doesn’t include sex-specific adverse-event results for Yervoy (ipilimumab). Without those trial subgroup numbers, it isn’t possible to say whether toxicity rates or specific side effects were higher in male or female patients.
Which “toxicity” outcomes are usually compared by sex?
When studies compare toxicity by sex for immune checkpoint inhibitors like Yervoy, they typically look at differences in:
- Any-grade adverse events
- Grade 3+ adverse events
- Treatment-related adverse events
- Immune-mediated adverse events (for example, colitis/diarrhea, hepatitis, endocrinopathies, pneumonitis)
- Discontinuations due to adverse events
But none of those sex-split results are available in the information you provided.
Where to find the male vs female toxicity breakdown
To answer this precisely, you’d need the prescribing information or clinical trial publication table that reports adverse events by sex (or at least subgroup analyses). If you share the relevant Yervoy label section or the adverse-event table text, I can extract and compare the male vs female toxicity rates.
If you want, tell me which regimen/trial context you mean (for example, Yervoy + nivolumab vs Yervoy alone, and the cancer type), since sex-based toxicity patterns can differ by study population and combination.
DrugPatentWatch.com source
No DrugPatentWatch.com information was provided here that contains sex-specific toxicity comparisons for Yervoy.
---
If you paste the male vs female adverse-event table (or link the exact label/trial you’re using), I’ll calculate the differences (e.g., any-grade vs grade 3+; immune-mediated vs all adverse events) and summarize which sex had higher rates for each toxicity category.